卡匹色替联合氟维司群治疗激素受体阳性、HER2阴性晚期乳腺癌患者(CAPItello-291):3期随机双盲安慰剂对照试验的患者报告结局
CAPItello-291是一项在19个国家193家医院开展的3期随机双盲安慰剂对照试验,评估卡匹色替联合氟维司群对比安慰剂联合氟维司群的患者报告结局。结果显示,卡匹色替联合氟维司群组总体健康状况/生活质量恶化时间延长(HR 0.70,95%CI 0.53-0.92),除腹泻外其他健康相关生活质量维度与氟维司群相似。
要点
- 卡匹色替联合氟维司群组总体健康状况/生活质量恶化中位时间为24.9个月,安慰剂联合氟维司群组为12.0个月(HR 0.70,95%CI 0.53-0.92)。
- 卡匹色替联合氟维司群组腹泻恶化风险高于安慰剂联合氟维司群组(HR 2.75,95%CI 2.01-3.81)。
- 两组多数患者报告治疗副作用困扰为「完全没有」或「有一点」。
核心结论
- CAPItello-291的患者报告结局显示,卡匹色替联合氟维司群延迟了总体健康状况/生活质量的恶化时间,并与其他健康相关生活质量维度(除腹泻症状外)的维持情况与氟维司群相似。
- 结合临床疗效和可控的安全性特征,这些探索性结果进一步支持卡匹色替联合氟维司群在该人群中的正向获益-风险特征。
研究设计与样本
- 3期随机双盲安慰剂对照试验,在19个国家的193家医院和癌症中心开展。
- 纳入年龄≥18岁(日本≥20岁)、任何绝经状态女性或男性、激素受体阳性HER2阴性局部晚期或转移性乳腺癌患者,在芳香化酶抑制剂治疗期间或之后出现复发或疾病进展,允许既往CDK4/6抑制剂治疗。
- 患者按1:1随机分配接受口服卡匹色替400 mg(每日两次,用药4天停3天)联合肌内注射氟维司群500 mg(前三次每14天一次,之后每28天一次)或安慰剂联合匹配的氟维司群给药。
- 患者报告结局采用EORTC QLQ-C30、QLQ-BR23、PRO-CTCAE和PGI-TT问卷评估,在基线和预设时间点收集数据。
- 患者报告结局在全部随机分配且基线评估可评价、至少一次基线后可评价评估的患者中分析。
主要发现
- EORTC QLQ-C30总体健康状况/生活质量评分自基线维持,两组在整个研究期间相似(卡匹色替联合氟维司群组自基线平均变化-2.5[95%CI -4.5至-0.6] vs 安慰剂联合氟维司群组-5.6[-7.9至-3.4];治疗差异3.1[95%CI 0.2至6.0])。
- EORTC QLQ-C30总体健康状况/生活质量恶化中位时间在卡匹色替联合氟维司群组为24.9个月(95%CI 13.8至未达到),安慰剂联合氟维司群组为12.0个月(10.2至15.7)(HR 0.70,95%CI 0.53至0.92)。
- 所有EORTC QLQ-C30和QLQ-BR23亚量表评分的恶化时间HR在两组间差异不大,但腹泻在卡匹色替联合氟维司群组较安慰剂联合氟维司群组更差(HR 2.75,95%CI 2.01-3.81)。
- PRO-CTCAE症状评估中,报告稀便或水样便「经常」或「几乎持续」的患者比例在第1周期第15天卡匹色替联合氟维司群组较安慰剂联合氟维司群组高29%,随后周期下降。
- 其他PRO-CTCAE报告的症状(皮疹、口腔或咽喉溃疡、皮肤瘙痒、手足麻木或刺痛)在两组多数患者中整个治疗期间缺失或为轻度。
关键数值与推荐
- EORTC QLQ-C30总体健康状况/生活质量恶化中位时间:卡匹色替联合氟维司群组24.9个月(95%CI 13.8至未达到) vs 安慰剂联合氟维司群组12.0个月(10.2至15.7),HR 0.70(95%CI 0.53至0.92)。
- EORTC QLQ-C30总体健康状况/生活质量自基线平均变化:卡匹色替联合氟维司群组-2.5(95%CI -4.5至-0.6) vs 安慰剂联合氟维司群组-5.6(-7.9至-3.4),治疗差异3.1(95%CI 0.2至6.0)。
- 腹泻恶化时间:卡匹色替联合氟维司群组较安慰剂联合氟维司群组更差,HR 2.75(95%CI 2.01-3.81)。
- 报告稀便或水样便「经常」或「几乎持续」的患者比例:第1周期第15天卡匹色替联合氟维司群组较安慰剂联合氟维司群组高29%。
临床怎么用
- 患者报告结局并非为统计学比较而前瞻性检验效能设计,结果为探索性分析。
- 根据PGI-TT,两组多数患者报告治疗副作用困扰为「完全没有」或「有一点」。
- 作者认为,这些探索性结果进一步支持卡匹色替联合氟维司群在该人群中的正向获益-风险特征。
局限性
- 患者报告结局未进行前瞻性统计学比较效能设计。
- 患者报告结局相关终点为次要终点或预先定义的探索性终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: CAPItello-291 is an ongoing phase 3 trial in which capivasertib-fulvestrant significantly improved progression-free survival versus placebo-fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer who had relapse or disease progression during or after aromatase inhibitor treatment, in both the overall population and in patients with PIK3CA, AKT1, or PTEN-altered tumours. This study further explored patient-reported health-related quality of life (HRQOL), functioning, symptoms, and symptom tolerability in CAPItello-291. METHODS: This phase 3, randomised, double-blind, placebo-controlled trial, which was conducted across 193 hospitals and cancer centres in 19 countries, enrolled women with any menopausal status or men, aged ≥18 years (≥20 years in Japan), with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer who had relapse or disease progression during or after treatment with an aromatase inhibitor, with or without previous cyclin-dependent kinase (CDK) 4 or 6 inhibitor therapy. Patients had an Eastern Cooperative Oncology Group/WHO performance score of 0 or 1 and could have received up to two previous lines of endocrine therapy and up to one previous line of chemotherapy for advanced disease. Patients were randomly assigned (1:1) using block randomisation (stratified according to the presence or absence of liver metastases, previous use of a CDK4/6 inhibitor [yes vs no], and geographical region) to receive oral capivasertib 400 mg (twice daily for 4 days, followed by 3 days off) plus intramuscular fulvestrant 500 mg (every 14 days for the first three injections, then every 28 days) or placebo with matching fulvestrant dosing. The dual primary endpoint of the trial was investigator-assessed progression-free survival assessed both in the overall population and among patients with PIK3CA, AKT1, or PTEN-altered tumours. The EORTC Quality of Life Questionnaire 30-item core module (QLQ-C30) and breast module (QLQ-BR23), Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), and Patient Global Impression of Treatment Tolerability (PGI-TT) questionnaires were used to assess patient-reported outcomes. Evaluation of EORTC QLQ-C30 and EORTC QLQ-BR23 were secondary endpoints and evaluation of PRO-CTCAE and PGI-TT were pre-defined exploratory endpoints, and these endpoints are the subject of analysis in this Article. Data were collected at baseline and prespecified timepoints. Patient-reported outcomes were analysed in all randomly assigned patients with an evaluable baseline assessment and at least one evaluable post-baseline assessment. Change from baseline was assessed using mixed model with repeated measures for EORTC QLQ-C30 and summarised for QLQ-BR23. Time to deterioration was described using the Kaplan-Meier method. PGI-TT and PRO-CTCAE responses were summarised at each treatment cycle. Patient-reported outcomes were not prospectively powered for statistical comparison. The trial is registered with ClinicalTrials.gov, NCT04305496. FINDINGS: Between June 2, 2020, and Oct 13, 2021, 901 patients were enrolled, of whom 708 patients were randomly assigned to receive capivasertib-fulvestrant (n=355) or placebo-fulvestrant (n=353). The median age of the patients was 59 years (IQR 51-67) in the capivasertib-fulvestrant group and 58 years (IQR 49-66) in the placebo-fulvestrant group. At data cutoff (Aug 15, 2022), the median duration of follow-up for progression-free survival in censored patients was 13·0 months (IQR 9·1-16·7) for capivasertib-fulvestrant and 12·7 months (IQR 2·0-16·4) for placebo-fulvestrant in the overall population. EORTC QLQ-C30 global health status/quality of life (GHS/QOL) scores were maintained from baseline and were similar between treatment groups throughout the study period (difference in mean change from baseline of -2·5 [95% CI -4·5 to -0·6] with capivasertib-fulvestrant vs -5·6 [-7·9 to -3·4] with placebo-fulvestrant; treatment difference 3·1 [95% CI 0·2 to 6·0]). Median time to deterioration in EORTC QLQ-C30 GHS/QOL was 24·9 months (95% CI 13·8 to not reached) in the capivasertib-fulvestrant group and 12·0 months (10·2 to 15·7) in the placebo-fulvestrant group (hazard ratio [HR] 0·70, 95% CI 0·53 to 0·92). Time to deterioration HRs for all EORTC QLQ-C30 and QLQ-BR23 subscale scores showed little difference between the treatment groups, except for diarrhoea, which was worse in the capivasertib-fulvestrant group than in the placebo-fulvestrant group (HR 2·75, 95% CI 2·01-3·81). In PRO-CTCAE symptom assessment, the proportion of patients reporting loose and watery stools "frequently" or "almost constantly" was 29% higher at cycle 1, day 15 in the capivasertib-fulvestrant group than in the placebo-fulvestrant group, decreasing at subsequent cycles. Other PRO-CTCAE-reported symptoms (rash, mouth or throat sores, itchy skin, and numbness or tingling in hands or feet) were absent or mild in most patients in both groups throughout treatment. According to the PGI-TT, most patients in both groups reported "not at all" or "a little bit" of bother from treatment side-effects. INTERPRETATION: Patient-reported outcomes from CAPItello-291 demonstrated that capivasertib-fulvestrant delayed time to deterioration of GHS/QOL and maintained other dimensions of HRQOL (except symptoms of diarrhoea) similarly to fulvestrant. With the clinical efficacy and manageable safety profile, these exploratory results further support the positive benefit-risk profile of capivasertib-fulvestrant in this population. FUNDING: AstraZeneca.
引用
- Oliveira M, Rugo HS, Howell SJ, et al. Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2024. PMID: 39214106. doi:10.1016/S1470-2045(24)00373-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。